#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1. Introduction
1-1	0-2	1.	_	_	_	_
1-2	3-15	Introduction	abstract	new	_	_

#Text=Rheumatoid arthritis ( RA ) is an autoimmune condition , characterized by symmetrical joint inflammation , that affects approximately 1 % of the world ’s population .
2-1	16-26	Rheumatoid	object|abstract[3]	new|new[3]	appos|appos	2-4[0_3]|2-4[0_3]
2-2	27-36	arthritis	abstract[3]	new[3]	_	_
2-3	37-38	(	_	_	_	_
2-4	39-41	RA	abstract	giv	coref	2-7[5_0]
2-5	42-43	)	_	_	_	_
2-6	44-46	is	_	_	_	_
2-7	47-49	an	abstract[5]	giv[5]	coref	3-1[0_5]
2-8	50-60	autoimmune	abstract[5]	giv[5]	_	_
2-9	61-70	condition	abstract[5]	giv[5]	_	_
2-10	71-72	,	_	_	_	_
2-11	73-86	characterized	_	_	_	_
2-12	87-89	by	_	_	_	_
2-13	90-101	symmetrical	abstract[6]	new[6]	_	_
2-14	102-107	joint	abstract[6]	new[6]	_	_
2-15	108-120	inflammation	abstract[6]	new[6]	_	_
2-16	121-122	,	_	_	_	_
2-17	123-127	that	_	_	_	_
2-18	128-135	affects	_	_	_	_
2-19	136-149	approximately	quantity[7]	new[7]	_	_
2-20	150-151	1	quantity[7]	new[7]	_	_
2-21	152-153	%	quantity[7]	new[7]	_	_
2-22	154-156	of	quantity[7]	new[7]	_	_
2-23	157-160	the	quantity[7]|abstract[9]	new[7]|new[9]	_	_
2-24	161-166	world	quantity[7]|place[8]|abstract[9]	new[7]|new[8]|new[9]	_	_
2-25	167-169	’s	quantity[7]|place[8]|abstract[9]	new[7]|new[8]|new[9]	_	_
2-26	170-180	population	quantity[7]|abstract[9]	new[7]|new[9]	_	_
2-27	181-182	.	_	_	_	_

#Text=RA is characterized mainly by synovium hyperplasia and a joint destruction process .
3-1	183-185	RA	abstract	giv	coref	4-24
3-2	186-188	is	_	_	_	_
3-3	189-202	characterized	_	_	_	_
3-4	203-209	mainly	_	_	_	_
3-5	210-212	by	_	_	_	_
3-6	213-221	synovium	place|abstract[12]	new|new[12]	_	_
3-7	222-233	hyperplasia	abstract[12]	new[12]	_	_
3-8	234-237	and	_	_	_	_
3-9	238-239	a	abstract[14]	new[14]	coref	7-34[52_14]
3-10	240-245	joint	abstract[14]	new[14]	_	_
3-11	246-257	destruction	event|abstract[14]	new|new[14]	coref	16-31
3-12	258-265	process	abstract[14]	new[14]	_	_
3-13	266-267	.	_	_	_	_

#Text=In this scenario , immune cells and the inflammatory microenvironment that they create in affected joints are key components in the pathophysiology of RA .
4-1	268-270	In	_	_	_	_
4-2	271-275	this	event[15]	new[15]	_	_
4-3	276-284	scenario	event[15]	new[15]	_	_
4-4	285-286	,	_	_	_	_
4-5	287-293	immune	object[16]|abstract[17]	new[16]|new[17]	ana|coref|ana|coref	4-12[0_17]|14-29[117_16]|4-12[0_17]|14-29[117_16]
4-6	294-299	cells	object[16]|abstract[17]	new[16]|new[17]	_	_
4-7	300-303	and	abstract[17]	new[17]	_	_
4-8	304-307	the	abstract[17]|abstract[18]	new[17]|new[18]	coref	4-18[21_18]
4-9	308-320	inflammatory	abstract[17]|abstract[18]	new[17]|new[18]	_	_
4-10	321-337	microenvironment	abstract[17]|abstract[18]	new[17]|new[18]	_	_
4-11	338-342	that	_	_	_	_
4-12	343-347	they	abstract	giv	_	_
4-13	348-354	create	_	_	_	_
4-14	355-357	in	_	_	_	_
4-15	358-366	affected	place[20]	new[20]	_	_
4-16	367-373	joints	place[20]	new[20]	_	_
4-17	374-377	are	_	_	_	_
4-18	378-381	key	abstract[21]	giv[21]	_	_
4-19	382-392	components	abstract[21]	giv[21]	_	_
4-20	393-395	in	abstract[21]	giv[21]	_	_
4-21	396-399	the	abstract[21]|abstract[22]	giv[21]|new[22]	ana	5-3[0_22]
4-22	400-415	pathophysiology	abstract[21]|abstract[22]	giv[21]|new[22]	_	_
4-23	416-418	of	abstract[21]|abstract[22]	giv[21]|new[22]	_	_
4-24	419-421	RA	abstract[21]|abstract[22]|abstract	giv[21]|new[22]|giv	coref	6-1
4-25	422-423	.	_	_	_	_

#Text=Moreover , it is well-described that during the inflammatory stages of the disease , extra-articular manifestations are common , which involve other tissues or organs .
5-1	424-432	Moreover	_	_	_	_
5-2	433-434	,	_	_	_	_
5-3	435-437	it	abstract	giv	_	_
5-4	438-440	is	_	_	_	_
5-5	441-455	well-described	_	_	_	_
5-6	456-460	that	_	_	_	_
5-7	461-467	during	_	_	_	_
5-8	468-471	the	abstract[25]	new[25]	_	_
5-9	472-484	inflammatory	abstract[25]	new[25]	_	_
5-10	485-491	stages	abstract[25]	new[25]	_	_
5-11	492-494	of	abstract[25]	new[25]	_	_
5-12	495-498	the	abstract[25]|abstract[26]	new[25]|new[26]	coref	7-22[0_26]
5-13	499-506	disease	abstract[25]|abstract[26]	new[25]|new[26]	_	_
5-14	507-508	,	_	_	_	_
5-15	509-524	extra-articular	abstract[27]	new[27]	_	_
5-16	525-539	manifestations	abstract[27]	new[27]	_	_
5-17	540-543	are	_	_	_	_
5-18	544-550	common	_	_	_	_
5-19	551-552	,	_	_	_	_
5-20	553-558	which	_	_	_	_
5-21	559-566	involve	_	_	_	_
5-22	567-572	other	object[28]	new[28]	coref	15-12[124_28]
5-23	573-580	tissues	object[28]	new[28]	_	_
5-24	581-583	or	_	_	_	_
5-25	584-590	organs	object	new	_	_
5-26	591-592	.	_	_	_	_

#Text=RA patients are at risk of systemic complications and several co-morbidities , including osteoporosis and frequent vertebral and hip fragility fractures .
6-1	593-595	RA	abstract|person[31]	giv|new[31]	coref|coref|coref|coref	7-8|7-8[42_31]|7-8|7-8[42_31]
6-2	596-604	patients	person[31]	new[31]	_	_
6-3	605-608	are	_	_	_	_
6-4	609-611	at	_	_	_	_
6-5	612-616	risk	abstract[32]	new[32]	coref	7-17[45_32]
6-6	617-619	of	abstract[32]	new[32]	_	_
6-7	620-628	systemic	abstract[32]|abstract[33]	new[32]|new[33]	_	_
6-8	629-642	complications	abstract[32]|abstract[33]	new[32]|new[33]	_	_
6-9	643-646	and	abstract[32]	new[32]	_	_
6-10	647-654	several	abstract[32]|abstract[34]	new[32]|new[34]	_	_
6-11	655-669	co-morbidities	abstract[32]|abstract[34]	new[32]|new[34]	_	_
6-12	670-671	,	abstract[32]|abstract[34]	new[32]|new[34]	_	_
6-13	672-681	including	abstract[32]|abstract[34]	new[32]|new[34]	_	_
6-14	682-694	osteoporosis	abstract[32]|abstract[34]|abstract	new[32]|new[34]|new	_	_
6-15	695-698	and	abstract[32]|abstract[34]	new[32]|new[34]	_	_
6-16	699-707	frequent	abstract[32]|abstract[34]|event[37]	new[32]|new[34]|new[37]	coref	7-5[40_37]
6-17	708-717	vertebral	abstract[32]|abstract[34]|event[37]	new[32]|new[34]|new[37]	_	_
6-18	718-721	and	abstract[32]|abstract[34]|event[37]	new[32]|new[34]|new[37]	_	_
6-19	722-725	hip	abstract[32]|abstract[34]|event[37]	new[32]|new[34]|new[37]	_	_
6-20	726-735	fragility	abstract[32]|abstract[34]|abstract|event[37]	new[32]|new[34]|new|new[37]	_	_
6-21	736-745	fractures	abstract[32]|abstract[34]|event[37]	new[32]|new[34]|new[37]	_	_
6-22	746-747	.	_	_	_	_

#Text=The incidence rate of overall fractures in RA patients is 33 per 1000 person-years , and the risk is increased with disease activity and associated with overexpression of pro-inflammatory cytokines that can disturb the bone remodeling process .
7-1	748-751	The	abstract[39]	new[39]	_	_
7-2	752-761	incidence	abstract|abstract[39]	new|new[39]	_	_
7-3	762-766	rate	abstract[39]	new[39]	_	_
7-4	767-769	of	abstract[39]	new[39]	_	_
7-5	770-777	overall	abstract[39]|event[40]	new[39]|giv[40]	_	_
7-6	778-787	fractures	abstract[39]|event[40]	new[39]|giv[40]	_	_
7-7	788-790	in	abstract[39]|event[40]	new[39]|giv[40]	_	_
7-8	791-793	RA	abstract[39]|event[40]|abstract|person[42]	new[39]|giv[40]|giv|giv[42]	coref|coref	8-24|8-24
7-9	794-802	patients	abstract[39]|event[40]|person[42]	new[39]|giv[40]|giv[42]	_	_
7-10	803-805	is	_	_	_	_
7-11	806-808	33	quantity[43]	new[43]	_	_
7-12	809-812	per	quantity[43]	new[43]	_	_
7-13	813-817	1000	quantity[43]|quantity[44]	new[43]|new[44]	_	_
7-14	818-830	person-years	quantity[43]|quantity[44]	new[43]|new[44]	_	_
7-15	831-832	,	_	_	_	_
7-16	833-836	and	_	_	_	_
7-17	837-840	the	abstract[45]	giv[45]	_	_
7-18	841-845	risk	abstract[45]	giv[45]	_	_
7-19	846-848	is	_	_	_	_
7-20	849-858	increased	_	_	_	_
7-21	859-863	with	_	_	_	_
7-22	864-871	disease	abstract|abstract[47]	giv|new[47]	coref|coref|coref|coref	11-11|21-12[196_47]|11-11|21-12[196_47]
7-23	872-880	activity	abstract[47]	new[47]	_	_
7-24	881-884	and	_	_	_	_
7-25	885-895	associated	_	_	_	_
7-26	896-900	with	_	_	_	_
7-27	901-915	overexpression	abstract[48]	new[48]	_	_
7-28	916-918	of	abstract[48]	new[48]	_	_
7-29	919-935	pro-inflammatory	abstract[48]|abstract[49]	new[48]|new[49]	coref	11-25[85_49]
7-30	936-945	cytokines	abstract[48]|abstract[49]	new[48]|new[49]	_	_
7-31	946-950	that	_	_	_	_
7-32	951-954	can	_	_	_	_
7-33	955-962	disturb	_	_	_	_
7-34	963-966	the	abstract[52]	giv[52]	coref	8-20[59_52]
7-35	967-971	bone	object|abstract[52]	new|giv[52]	_	_
7-36	972-982	remodeling	event|abstract[52]	new|giv[52]	_	_
7-37	983-990	process	abstract[52]	giv[52]	_	_
7-38	991-992	.	_	_	_	_

#Text=Over the last decades , animal models — especially the rodent models — have been crucial tools for understanding the biologic process of RA , and their use can aid in developing new therapeutic strategies for fracture healing in RA inflammatory conditions .
8-1	993-997	Over	_	_	_	_
8-2	998-1001	the	time[53]	new[53]	_	_
8-3	1002-1006	last	time[53]	new[53]	_	_
8-4	1007-1014	decades	time[53]	new[53]	_	_
8-5	1015-1016	,	_	_	_	_
8-6	1017-1023	animal	person|abstract[55]	new|new[55]	appos|coref|appos|coref	8-9[57_55]|9-6|8-9[57_55]|9-6
8-7	1024-1030	models	abstract[55]	new[55]	_	_
8-8	1031-1032	—	_	_	_	_
8-9	1033-1043	especially	abstract[57]	giv[57]	coref	8-16[58_57]
8-10	1044-1047	the	abstract[57]	giv[57]	_	_
8-11	1048-1054	rodent	animal|abstract[57]	new|giv[57]	_	_
8-12	1055-1061	models	abstract[57]	giv[57]	_	_
8-13	1062-1063	—	_	_	_	_
8-14	1064-1068	have	_	_	_	_
8-15	1069-1073	been	_	_	_	_
8-16	1074-1081	crucial	abstract[58]	giv[58]	ana	8-27[0_58]
8-17	1082-1087	tools	abstract[58]	giv[58]	_	_
8-18	1088-1091	for	_	_	_	_
8-19	1092-1105	understanding	_	_	_	_
8-20	1106-1109	the	abstract[59]	giv[59]	coref	11-43[92_59]
8-21	1110-1118	biologic	abstract[59]	giv[59]	_	_
8-22	1119-1126	process	abstract[59]	giv[59]	_	_
8-23	1127-1129	of	abstract[59]	giv[59]	_	_
8-24	1130-1132	RA	abstract[59]|abstract	giv[59]|giv	coref	8-40
8-25	1133-1134	,	_	_	_	_
8-26	1135-1138	and	_	_	_	_
8-27	1139-1144	their	abstract|abstract[62]	giv|new[62]	coref|coref|coref|coref	9-1[70_0]|17-6[145_62]|9-1[70_0]|17-6[145_62]
8-28	1145-1148	use	abstract[62]	new[62]	_	_
8-29	1149-1152	can	_	_	_	_
8-30	1153-1156	aid	_	_	_	_
8-31	1157-1159	in	_	_	_	_
8-32	1160-1170	developing	_	_	_	_
8-33	1171-1174	new	abstract[63]	new[63]	coref	11-49[93_63]
8-34	1175-1186	therapeutic	abstract[63]	new[63]	_	_
8-35	1187-1197	strategies	abstract[63]	new[63]	_	_
8-36	1198-1201	for	_	_	_	_
8-37	1202-1210	fracture	abstract	new	_	_
8-38	1211-1218	healing	_	_	_	_
8-39	1219-1221	in	_	_	_	_
8-40	1222-1224	RA	abstract|abstract[66]	giv|new[66]	coref|coref|coref|coref	9-18|17-29[154_66]|9-18|17-29[154_66]
8-41	1225-1237	inflammatory	abstract[66]	new[66]	_	_
8-42	1238-1248	conditions	abstract[66]	new[66]	_	_
8-43	1249-1250	.	_	_	_	_

#Text=Collagen induced-arthritis ( CIA ) animal models have been one of the most widely used models in RA research .
9-1	1251-1259	Collagen	organization|abstract[70]	new|giv[70]	coref|coref	9-12[72_70]|9-12[72_70]
9-2	1260-1277	induced-arthritis	abstract[70]	giv[70]	_	_
9-3	1278-1279	(	abstract[70]	giv[70]	_	_
9-4	1280-1283	CIA	abstract|abstract[70]	new|giv[70]	coref	10-6
9-5	1284-1285	)	abstract[70]	giv[70]	_	_
9-6	1286-1292	animal	person|abstract[70]	giv|giv[70]	coref	10-10
9-7	1293-1299	models	abstract[70]	giv[70]	_	_
9-8	1300-1304	have	_	_	_	_
9-9	1305-1309	been	_	_	_	_
9-10	1310-1313	one	abstract[71]	new[71]	_	_
9-11	1314-1316	of	abstract[71]	new[71]	_	_
9-12	1317-1320	the	abstract[71]|abstract[72]	new[71]|giv[72]	coref	20-9[174_72]
9-13	1321-1325	most	abstract[71]|abstract[72]	new[71]|giv[72]	_	_
9-14	1326-1332	widely	abstract[71]|abstract[72]	new[71]|giv[72]	_	_
9-15	1333-1337	used	abstract[71]|abstract[72]	new[71]|giv[72]	_	_
9-16	1338-1344	models	abstract[71]|abstract[72]	new[71]|giv[72]	_	_
9-17	1345-1347	in	abstract[71]|abstract[72]	new[71]|giv[72]	_	_
9-18	1348-1350	RA	abstract[71]|abstract[72]|abstract|abstract[74]	new[71]|giv[72]|giv|new[74]	coref|coref	10-14|10-14
9-19	1351-1359	research	abstract[71]|abstract[72]|abstract[74]	new[71]|giv[72]|new[74]	_	_
9-20	1360-1361	.	_	_	_	_

#Text=Originally described by Trentham , CIA is a reproducible animal experimental model of RA .
10-1	1362-1372	Originally	_	_	_	_
10-2	1373-1382	described	_	_	_	_
10-3	1383-1385	by	_	_	_	_
10-4	1386-1394	Trentham	person	new	_	_
10-5	1395-1396	,	_	_	_	_
10-6	1397-1400	CIA	abstract	giv	coref	10-8[78_0]
10-7	1401-1403	is	_	_	_	_
10-8	1404-1405	a	abstract[78]	giv[78]	coref	11-38[91_78]
10-9	1406-1418	reproducible	abstract[78]	giv[78]	_	_
10-10	1419-1425	animal	person|abstract[78]	giv|giv[78]	_	_
10-11	1426-1438	experimental	abstract[78]	giv[78]	_	_
10-12	1439-1444	model	abstract[78]	giv[78]	_	_
10-13	1445-1447	of	abstract[78]	giv[78]	_	_
10-14	1448-1450	RA	abstract[78]|abstract	giv[78]|giv	coref	11-7[81_0]
10-15	1451-1452	.	_	_	_	_

#Text=In fact , the similarity to human RA regarding the disease clinical , histological , and immunological signals — including high articular levels of inflammatory cytokines — like tumor necrosis factor-α ( TNF-α ) , make it an invaluable model to study the pathologic process and to search new therapeutic strategies .
11-1	1453-1455	In	_	_	_	_
11-2	1456-1460	fact	_	_	_	_
11-3	1461-1462	,	_	_	_	_
11-4	1463-1466	the	abstract[80]	new[80]	_	_
11-5	1467-1477	similarity	abstract[80]	new[80]	_	_
11-6	1478-1480	to	abstract[80]	new[80]	_	_
11-7	1481-1486	human	abstract[80]|abstract[81]	new[80]|giv[81]	coref	14-4[0_81]
11-8	1487-1489	RA	abstract[80]|abstract[81]	new[80]|giv[81]	_	_
11-9	1490-1499	regarding	_	_	_	_
11-10	1500-1503	the	abstract[83]	new[83]	_	_
11-11	1504-1511	disease	abstract|abstract[83]	giv|new[83]	_	_
11-12	1512-1520	clinical	abstract[83]	new[83]	_	_
11-13	1521-1522	,	abstract[83]	new[83]	_	_
11-14	1523-1535	histological	abstract[83]	new[83]	_	_
11-15	1536-1537	,	abstract[83]	new[83]	_	_
11-16	1538-1541	and	abstract[83]	new[83]	_	_
11-17	1542-1555	immunological	abstract[83]	new[83]	_	_
11-18	1556-1563	signals	abstract[83]	new[83]	_	_
11-19	1564-1565	—	abstract[83]	new[83]	_	_
11-20	1566-1575	including	abstract[83]	new[83]	_	_
11-21	1576-1580	high	abstract[83]|abstract[84]	new[83]|new[84]	_	_
11-22	1581-1590	articular	abstract[83]|abstract[84]	new[83]|new[84]	_	_
11-23	1591-1597	levels	abstract[83]|abstract[84]	new[83]|new[84]	_	_
11-24	1598-1600	of	abstract[83]|abstract[84]	new[83]|new[84]	_	_
11-25	1601-1613	inflammatory	abstract[83]|abstract[84]|abstract[85]	new[83]|new[84]|giv[85]	_	_
11-26	1614-1623	cytokines	abstract[83]|abstract[84]|abstract[85]	new[83]|new[84]|giv[85]	_	_
11-27	1624-1625	—	abstract[83]|abstract[84]	new[83]|new[84]	_	_
11-28	1626-1630	like	abstract[83]|abstract[84]	new[83]|new[84]	_	_
11-29	1631-1636	tumor	abstract[83]|abstract[84]|abstract|abstract[88]	new[83]|new[84]|new|new[88]	appos|appos	11-33[0_88]|11-33[0_88]
11-30	1637-1645	necrosis	abstract[83]|abstract[84]|abstract|abstract[88]	new[83]|new[84]|new|new[88]	_	_
11-31	1646-1654	factor-α	abstract[83]|abstract[84]|abstract[88]	new[83]|new[84]|new[88]	_	_
11-32	1655-1656	(	_	_	_	_
11-33	1657-1662	TNF-α	abstract	giv	ana	11-37
11-34	1663-1664	)	_	_	_	_
11-35	1665-1666	,	_	_	_	_
11-36	1667-1671	make	_	_	_	_
11-37	1672-1674	it	abstract	giv	coref	12-22
11-38	1675-1677	an	abstract[91]	giv[91]	coref	12-4[96_91]
11-39	1678-1688	invaluable	abstract[91]	giv[91]	_	_
11-40	1689-1694	model	abstract[91]	giv[91]	_	_
11-41	1695-1697	to	_	_	_	_
11-42	1698-1703	study	_	_	_	_
11-43	1704-1707	the	abstract[92]	giv[92]	_	_
11-44	1708-1718	pathologic	abstract[92]	giv[92]	_	_
11-45	1719-1726	process	abstract[92]	giv[92]	_	_
11-46	1727-1730	and	_	_	_	_
11-47	1731-1733	to	_	_	_	_
11-48	1734-1740	search	_	_	_	_
11-49	1741-1744	new	abstract[93]	giv[93]	_	_
11-50	1745-1756	therapeutic	abstract[93]	giv[93]	_	_
11-51	1757-1767	strategies	abstract[93]	giv[93]	_	_
11-52	1768-1769	.	_	_	_	_

#Text=The response to rat CIA has been reported to involve macrophages , T and B lymphocytes , and mediators such as TNF-α , Interleukin ( IL)-1β , IL-6 , and IL-17 .
12-1	1770-1773	The	abstract[94]	new[94]	coref	13-3[107_94]
12-2	1774-1782	response	abstract[94]	new[94]	_	_
12-3	1783-1785	to	abstract[94]	new[94]	_	_
12-4	1786-1789	rat	abstract[94]|animal|abstract[96]	new[94]|new|giv[96]	coref|coref	13-7[108_96]|13-7[108_96]
12-5	1790-1793	CIA	abstract[94]|abstract[96]	new[94]|giv[96]	_	_
12-6	1794-1797	has	_	_	_	_
12-7	1798-1802	been	_	_	_	_
12-8	1803-1811	reported	_	_	_	_
12-9	1812-1814	to	_	_	_	_
12-10	1815-1822	involve	_	_	_	_
12-11	1823-1834	macrophages	animal	new	_	_
12-12	1835-1836	,	_	_	_	_
12-13	1837-1838	T	person	new	_	_
12-14	1839-1842	and	_	_	_	_
12-15	1843-1844	B	place|person[100]	new|new[100]	_	_
12-16	1845-1856	lymphocytes	person[100]	new[100]	_	_
12-17	1857-1858	,	_	_	_	_
12-18	1859-1862	and	_	_	_	_
12-19	1863-1872	mediators	person[101]	new[101]	_	_
12-20	1873-1877	such	person[101]	new[101]	_	_
12-21	1878-1880	as	person[101]	new[101]	_	_
12-22	1881-1886	TNF-α	person[101]|abstract	new[101]|giv	_	_
12-23	1887-1888	,	_	_	_	_
12-24	1889-1900	Interleukin	object	new	_	_
12-25	1901-1902	(	_	_	_	_
12-26	1903-1909	IL)-1β	abstract	new	_	_
12-27	1910-1911	,	_	_	_	_
12-28	1912-1916	IL-6	abstract	new	coref	20-53[190_0]
12-29	1917-1918	,	_	_	_	_
12-30	1919-1922	and	_	_	_	_
12-31	1923-1928	IL-17	abstract	new	_	_
12-32	1929-1930	.	_	_	_	_

#Text=Nonetheless , the systemic response in this model has not been well characterized so far .
13-1	1931-1942	Nonetheless	_	_	_	_
13-2	1943-1944	,	_	_	_	_
13-3	1945-1948	the	abstract[107]	giv[107]	_	_
13-4	1949-1957	systemic	abstract[107]	giv[107]	_	_
13-5	1958-1966	response	abstract[107]	giv[107]	_	_
13-6	1967-1969	in	abstract[107]	giv[107]	_	_
13-7	1970-1974	this	abstract[107]|abstract[108]	giv[107]|giv[108]	coref	16-15[0_108]
13-8	1975-1980	model	abstract[107]|abstract[108]	giv[107]|giv[108]	_	_
13-9	1981-1984	has	_	_	_	_
13-10	1985-1988	not	_	_	_	_
13-11	1989-1993	been	_	_	_	_
13-12	1994-1998	well	_	_	_	_
13-13	1999-2012	characterized	_	_	_	_
13-14	2013-2015	so	_	_	_	_
13-15	2016-2019	far	_	_	_	_
13-16	2020-2021	.	_	_	_	_

#Text=Importantly , current RA treatments do not promote joint repair , and several efforts are being made to develop new therapies , especially based in cell approaches using mesenchymal stem/stromal cells ( MSC ) .
14-1	2022-2033	Importantly	_	_	_	_
14-2	2034-2035	,	_	_	_	_
14-3	2036-2043	current	abstract[110]	new[110]	_	_
14-4	2044-2046	RA	abstract|abstract[110]	giv|new[110]	coref	16-12
14-5	2047-2057	treatments	abstract[110]	new[110]	_	_
14-6	2058-2060	do	_	_	_	_
14-7	2061-2064	not	_	_	_	_
14-8	2065-2072	promote	_	_	_	_
14-9	2073-2078	joint	abstract[111]	new[111]	coref	15-43[133_111]
14-10	2079-2085	repair	abstract[111]	new[111]	_	_
14-11	2086-2087	,	_	_	_	_
14-12	2088-2091	and	_	_	_	_
14-13	2092-2099	several	abstract[112]	new[112]	_	_
14-14	2100-2107	efforts	abstract[112]	new[112]	_	_
14-15	2108-2111	are	_	_	_	_
14-16	2112-2117	being	_	_	_	_
14-17	2118-2122	made	_	_	_	_
14-18	2123-2125	to	_	_	_	_
14-19	2126-2133	develop	_	_	_	_
14-20	2134-2137	new	abstract[113]	new[113]	_	_
14-21	2138-2147	therapies	abstract[113]	new[113]	_	_
14-22	2148-2149	,	_	_	_	_
14-23	2150-2160	especially	_	_	_	_
14-24	2161-2166	based	_	_	_	_
14-25	2167-2169	in	_	_	_	_
14-26	2170-2174	cell	place|abstract[115]	new|new[115]	coref|coref	15-39|15-39
14-27	2175-2185	approaches	abstract[115]	new[115]	_	_
14-28	2186-2191	using	_	_	_	_
14-29	2192-2203	mesenchymal	animal|object[117]	new|giv[117]	appos|coref|appos|coref	14-33[0_117]|15-12|14-33[0_117]|15-12
14-30	2204-2216	stem/stromal	object[117]	giv[117]	_	_
14-31	2217-2222	cells	object[117]	giv[117]	_	_
14-32	2223-2224	(	_	_	_	_
14-33	2225-2228	MSC	object	giv	coref	15-1
14-34	2229-2230	)	_	_	_	_
14-35	2231-2232	.	_	_	_	_

#Text=MSC are multipotent progenitor cells with the potential to differentiate into mesenchymal lineage tissues ( e. g. , bone , cartilage , and adipose tissue ) , described to have immunomodulatory roles , being capable of recruiting different cell types and promoting tissue repair .
15-1	2233-2236	MSC	object	giv	coref	15-3[120_0]
15-2	2237-2240	are	_	_	_	_
15-3	2241-2252	multipotent	object[120]	giv[120]	coref	16-4[0_120]
15-4	2253-2263	progenitor	object[120]	giv[120]	_	_
15-5	2264-2269	cells	object[120]	giv[120]	_	_
15-6	2270-2274	with	object[120]	giv[120]	_	_
15-7	2275-2278	the	object[120]|abstract[121]	giv[120]|new[121]	_	_
15-8	2279-2288	potential	object[120]|abstract[121]	giv[120]|new[121]	_	_
15-9	2289-2291	to	_	_	_	_
15-10	2292-2305	differentiate	_	_	_	_
15-11	2306-2310	into	_	_	_	_
15-12	2311-2322	mesenchymal	abstract|object[124]	giv|giv[124]	appos|appos	15-19[0_124]|15-19[0_124]
15-13	2323-2330	lineage	abstract|object[124]	new|giv[124]	_	_
15-14	2331-2338	tissues	object[124]	giv[124]	_	_
15-15	2339-2340	(	_	_	_	_
15-16	2341-2343	e.	_	_	_	_
15-17	2344-2346	g.	_	_	_	_
15-18	2347-2348	,	_	_	_	_
15-19	2349-2353	bone	object	giv	appos	15-21
15-20	2354-2355	,	_	_	_	_
15-21	2356-2365	cartilage	object	giv	appos	15-24[128_0]
15-22	2366-2367	,	_	_	_	_
15-23	2368-2371	and	_	_	_	_
15-24	2372-2379	adipose	abstract|object[128]	new|giv[128]	coref|coref	19-12[0_128]|19-12[0_128]
15-25	2380-2386	tissue	object[128]	giv[128]	_	_
15-26	2387-2388	)	_	_	_	_
15-27	2389-2390	,	_	_	_	_
15-28	2391-2400	described	_	_	_	_
15-29	2401-2403	to	_	_	_	_
15-30	2404-2408	have	_	_	_	_
15-31	2409-2425	immunomodulatory	abstract[129]	new[129]	_	_
15-32	2426-2431	roles	abstract[129]	new[129]	_	_
15-33	2432-2433	,	_	_	_	_
15-34	2434-2439	being	_	_	_	_
15-35	2440-2447	capable	_	_	_	_
15-36	2448-2450	of	_	_	_	_
15-37	2451-2461	recruiting	_	_	_	_
15-38	2462-2471	different	abstract[131]	new[131]	_	_
15-39	2472-2476	cell	object|abstract[131]	giv|new[131]	_	_
15-40	2477-2482	types	abstract[131]	new[131]	_	_
15-41	2483-2486	and	_	_	_	_
15-42	2487-2496	promoting	_	_	_	_
15-43	2497-2503	tissue	object|abstract[133]	new|giv[133]	_	_
15-44	2504-2510	repair	abstract[133]	giv[133]	_	_
15-45	2511-2512	.	_	_	_	_

#Text=The transplantation of MSC has been reported to ameliorate or delay RA onset in CIA animals , partially mediated by inflammatory signaling suppression , and thereby reducing joint swelling and destruction .
16-1	2513-2516	The	event[134]	new[134]	coref	17-9[147_134]
16-2	2517-2532	transplantation	event[134]	new[134]	_	_
16-3	2533-2535	of	event[134]	new[134]	_	_
16-4	2536-2539	MSC	event[134]|object	new[134]|giv	coref	17-9
16-5	2540-2543	has	_	_	_	_
16-6	2544-2548	been	_	_	_	_
16-7	2549-2557	reported	_	_	_	_
16-8	2558-2560	to	_	_	_	_
16-9	2561-2571	ameliorate	_	_	_	_
16-10	2572-2574	or	_	_	_	_
16-11	2575-2580	delay	_	_	_	_
16-12	2581-2583	RA	abstract|abstract[137]	giv|new[137]	coref|coref	18-6[156_0]|18-6[156_0]
16-13	2584-2589	onset	abstract[137]	new[137]	_	_
16-14	2590-2592	in	abstract[137]	new[137]	_	_
16-15	2593-2596	CIA	abstract[137]|organization|animal[139]	new[137]|giv|new[139]	coref|coref|coref|coref	17-16|17-16[149_139]|17-16|17-16[149_139]
16-16	2597-2604	animals	abstract[137]|animal[139]	new[137]|new[139]	_	_
16-17	2605-2606	,	_	_	_	_
16-18	2607-2616	partially	_	_	_	_
16-19	2617-2625	mediated	_	_	_	_
16-20	2626-2628	by	_	_	_	_
16-21	2629-2641	inflammatory	abstract[141]	new[141]	_	_
16-22	2642-2651	signaling	abstract|abstract[141]	new|new[141]	_	_
16-23	2652-2663	suppression	abstract[141]	new[141]	_	_
16-24	2664-2665	,	_	_	_	_
16-25	2666-2669	and	_	_	_	_
16-26	2670-2677	thereby	_	_	_	_
16-27	2678-2686	reducing	_	_	_	_
16-28	2687-2692	joint	abstract[142]	new[142]	_	_
16-29	2693-2701	swelling	abstract[142]	new[142]	_	_
16-30	2702-2705	and	_	_	_	_
16-31	2706-2717	destruction	event	giv	_	_
16-32	2718-2719	.	_	_	_	_

#Text=Although the available evidence supports the use of MSC transplantation as a cell-based strategy in CIA animals , data on the biology of endogenous CIA animals-derived MSC in basal conditions is scarce .
17-1	2720-2728	Although	_	_	_	_
17-2	2729-2732	the	abstract[144]	new[144]	_	_
17-3	2733-2742	available	abstract[144]	new[144]	_	_
17-4	2743-2751	evidence	abstract[144]	new[144]	_	_
17-5	2752-2760	supports	_	_	_	_
17-6	2761-2764	the	abstract[145]	giv[145]	_	_
17-7	2765-2768	use	abstract[145]	giv[145]	_	_
17-8	2769-2771	of	abstract[145]	giv[145]	_	_
17-9	2772-2775	MSC	abstract[145]|object|event[147]	giv[145]|giv|giv[147]	coref|coref	17-24[153_0]|17-24[153_0]
17-10	2776-2791	transplantation	abstract[145]|event[147]	giv[145]|giv[147]	_	_
17-11	2792-2794	as	_	_	_	_
17-12	2795-2796	a	_	_	_	_
17-13	2797-2807	cell-based	_	_	_	_
17-14	2808-2816	strategy	_	_	_	_
17-15	2817-2819	in	_	_	_	_
17-16	2820-2823	CIA	organization|animal[149]	giv|giv[149]	coref|coref|coref|coref	17-25|20-16[176_149]|17-25|20-16[176_149]
17-17	2824-2831	animals	animal[149]	giv[149]	_	_
17-18	2832-2833	,	_	_	_	_
17-19	2834-2838	data	abstract[150]	new[150]	_	_
17-20	2839-2841	on	abstract[150]	new[150]	_	_
17-21	2842-2845	the	abstract[150]|abstract[151]	new[150]|new[151]	_	_
17-22	2846-2853	biology	abstract[150]|abstract[151]	new[150]|new[151]	_	_
17-23	2854-2856	of	abstract[150]|abstract[151]	new[150]|new[151]	_	_
17-24	2857-2867	endogenous	abstract[150]|abstract[151]|object[153]	new[150]|new[151]|giv[153]	coref	18-14[158_153]
17-25	2868-2871	CIA	abstract[150]|abstract[151]|organization|object[153]	new[150]|new[151]|giv|giv[153]	coref	19-5
17-26	2872-2887	animals-derived	abstract[150]|abstract[151]|object[153]	new[150]|new[151]|giv[153]	_	_
17-27	2888-2891	MSC	abstract[150]|abstract[151]|object[153]	new[150]|new[151]|giv[153]	_	_
17-28	2892-2894	in	abstract[150]|abstract[151]|object[153]	new[150]|new[151]|giv[153]	_	_
17-29	2895-2900	basal	abstract[150]|abstract[151]|object[153]|abstract[154]	new[150]|new[151]|giv[153]|giv[154]	coref	19-15[163_154]
17-30	2901-2911	conditions	abstract[150]|abstract[151]|object[153]|abstract[154]	new[150]|new[151]|giv[153]|giv[154]	_	_
17-31	2912-2914	is	_	_	_	_
17-32	2915-2921	scarce	_	_	_	_
17-33	2922-2923	.	_	_	_	_

#Text=Moreover , the impact of the systemic inflammatory condition on biological properties of endogenous MSC has not been explored yet .
18-1	2924-2932	Moreover	_	_	_	_
18-2	2933-2934	,	_	_	_	_
18-3	2935-2938	the	abstract[155]	new[155]	_	_
18-4	2939-2945	impact	abstract[155]	new[155]	_	_
18-5	2946-2948	of	abstract[155]	new[155]	_	_
18-6	2949-2952	the	abstract[155]|abstract[156]	new[155]|giv[156]	coref	19-25[0_156]
18-7	2953-2961	systemic	abstract[155]|abstract[156]	new[155]|giv[156]	_	_
18-8	2962-2974	inflammatory	abstract[155]|abstract[156]	new[155]|giv[156]	_	_
18-9	2975-2984	condition	abstract[155]|abstract[156]	new[155]|giv[156]	_	_
18-10	2985-2987	on	abstract[155]	new[155]	_	_
18-11	2988-2998	biological	abstract[155]|abstract[157]	new[155]|new[157]	_	_
18-12	2999-3009	properties	abstract[155]|abstract[157]	new[155]|new[157]	_	_
18-13	3010-3012	of	abstract[155]|abstract[157]	new[155]|new[157]	_	_
18-14	3013-3023	endogenous	abstract[155]|abstract[157]|object[158]	new[155]|new[157]|giv[158]	coref	19-32[169_158]
18-15	3024-3027	MSC	abstract[155]|abstract[157]|object[158]	new[155]|new[157]|giv[158]	_	_
18-16	3028-3031	has	_	_	_	_
18-17	3032-3035	not	_	_	_	_
18-18	3036-3040	been	_	_	_	_
18-19	3041-3049	explored	_	_	_	_
18-20	3050-3053	yet	_	_	_	_
18-21	3054-3055	.	_	_	_	_

#Text=Herein , we propose CIA as a reliable model to study bone regeneration in inflammatory conditions , and additionally we investigate the effect of RA induction on the biological behavior of endogenous MSC as crucial cells involved in repair/regeneration .
19-1	3056-3062	Herein	_	_	_	_
19-2	3063-3064	,	_	_	_	_
19-3	3065-3067	we	person	acc	ana	19-20
19-4	3068-3075	propose	_	_	_	_
19-5	3076-3079	CIA	abstract	giv	coref	20-16
19-6	3080-3082	as	_	_	_	_
19-7	3083-3084	a	_	_	_	_
19-8	3085-3093	reliable	_	_	_	_
19-9	3094-3099	model	_	_	_	_
19-10	3100-3102	to	_	_	_	_
19-11	3103-3108	study	_	_	_	_
19-12	3109-3113	bone	object|abstract[162]	giv|new[162]	coref|coref	20-21|20-21
19-13	3114-3126	regeneration	abstract[162]	new[162]	_	_
19-14	3127-3129	in	_	_	_	_
19-15	3130-3142	inflammatory	abstract[163]	giv[163]	coref	21-57[213_163]
19-16	3143-3153	conditions	abstract[163]	giv[163]	_	_
19-17	3154-3155	,	_	_	_	_
19-18	3156-3159	and	_	_	_	_
19-19	3160-3172	additionally	_	_	_	_
19-20	3173-3175	we	person	giv	ana	20-1
19-21	3176-3187	investigate	_	_	_	_
19-22	3188-3191	the	abstract[165]	new[165]	_	_
19-23	3192-3198	effect	abstract[165]	new[165]	_	_
19-24	3199-3201	of	abstract[165]	new[165]	_	_
19-25	3202-3204	RA	abstract[165]|organization|abstract[167]	new[165]|giv|new[167]	coref|coref|coref|coref	21-8|21-7[194_167]|21-8|21-7[194_167]
19-26	3205-3214	induction	abstract[165]|abstract[167]	new[165]|new[167]	_	_
19-27	3215-3217	on	abstract[165]|abstract[167]	new[165]|new[167]	_	_
19-28	3218-3221	the	abstract[165]|abstract[167]|abstract[168]	new[165]|new[167]|new[168]	_	_
19-29	3222-3232	biological	abstract[165]|abstract[167]|abstract[168]	new[165]|new[167]|new[168]	_	_
19-30	3233-3241	behavior	abstract[165]|abstract[167]|abstract[168]	new[165]|new[167]|new[168]	_	_
19-31	3242-3244	of	abstract[165]|abstract[167]|abstract[168]	new[165]|new[167]|new[168]	_	_
19-32	3245-3255	endogenous	abstract[165]|abstract[167]|abstract[168]|object[169]	new[165]|new[167]|new[168]|giv[169]	coref	20-30[0_169]
19-33	3256-3259	MSC	abstract[165]|abstract[167]|abstract[168]|object[169]	new[165]|new[167]|new[168]|giv[169]	_	_
19-34	3260-3262	as	abstract[165]|abstract[167]|abstract[168]	new[165]|new[167]|new[168]	_	_
19-35	3263-3270	crucial	abstract[165]|abstract[167]|abstract[168]	new[165]|new[167]|new[168]	_	_
19-36	3271-3276	cells	abstract[165]|abstract[167]|abstract[168]	new[165]|new[167]|new[168]	_	_
19-37	3277-3285	involved	_	_	_	_
19-38	3286-3288	in	_	_	_	_
19-39	3289-3308	repair/regeneration	event	new	_	_
19-40	3309-3310	.	_	_	_	_

#Text=Our results have shown that the combination of the two models is feasible and that CIA animals respond to the bone injury with a significant increase of systemic myeloid cells number and their co-stimulatory molecules ( CD40 and CD86 ) expression , accompanied by increased levels of IL-13 , IL-2 , and IL-6 in plasma .
20-1	3311-3314	Our	person|abstract[172]	giv|new[172]	_	_
20-2	3315-3322	results	abstract[172]	new[172]	_	_
20-3	3323-3327	have	_	_	_	_
20-4	3328-3333	shown	_	_	_	_
20-5	3334-3338	that	_	_	_	_
20-6	3339-3342	the	abstract[173]	new[173]	_	_
20-7	3343-3354	combination	abstract[173]	new[173]	_	_
20-8	3355-3357	of	abstract[173]	new[173]	_	_
20-9	3358-3361	the	abstract[173]|abstract[174]	new[173]|giv[174]	_	_
20-10	3362-3365	two	abstract[173]|abstract[174]	new[173]|giv[174]	_	_
20-11	3366-3372	models	abstract[173]|abstract[174]	new[173]|giv[174]	_	_
20-12	3373-3375	is	_	_	_	_
20-13	3376-3384	feasible	_	_	_	_
20-14	3385-3388	and	_	_	_	_
20-15	3389-3393	that	_	_	_	_
20-16	3394-3397	CIA	organization|animal[176]	giv|giv[176]	ana|ana	20-33[0_176]|20-33[0_176]
20-17	3398-3405	animals	animal[176]	giv[176]	_	_
20-18	3406-3413	respond	_	_	_	_
20-19	3414-3416	to	_	_	_	_
20-20	3417-3420	the	event[178]	new[178]	_	_
20-21	3421-3425	bone	object|event[178]	giv|new[178]	_	_
20-22	3426-3432	injury	event[178]	new[178]	_	_
20-23	3433-3437	with	_	_	_	_
20-24	3438-3439	a	abstract[179]	new[179]	_	_
20-25	3440-3451	significant	abstract[179]	new[179]	_	_
20-26	3452-3460	increase	abstract[179]	new[179]	_	_
20-27	3461-3463	of	abstract[179]	new[179]	_	_
20-28	3464-3472	systemic	abstract[179]|abstract[182]	new[179]|new[182]	_	_
20-29	3473-3480	myeloid	abstract[179]|object|abstract[182]	new[179]|new|new[182]	_	_
20-30	3481-3486	cells	abstract[179]|object|abstract[182]	new[179]|giv|new[182]	coref	21-18[199_0]
20-31	3487-3493	number	abstract[179]|abstract[182]	new[179]|new[182]	_	_
20-32	3494-3497	and	abstract[179]	new[179]	_	_
20-33	3498-3503	their	abstract[179]|animal|abstract[184]	new[179]|giv|new[184]	appos|appos	20-37[185_184]|20-37[185_184]
20-34	3504-3518	co-stimulatory	abstract[179]|abstract[184]	new[179]|new[184]	_	_
20-35	3519-3528	molecules	abstract[179]|abstract[184]	new[179]|new[184]	_	_
20-36	3529-3530	(	_	_	_	_
20-37	3531-3535	CD40	abstract[185]	giv[185]	_	_
20-38	3536-3539	and	abstract[185]	giv[185]	_	_
20-39	3540-3544	CD86	abstract[185]	giv[185]	_	_
20-40	3545-3546	)	_	_	_	_
20-41	3547-3557	expression	abstract	new	coref	21-27[202_0]
20-42	3558-3559	,	_	_	_	_
20-43	3560-3571	accompanied	_	_	_	_
20-44	3572-3574	by	_	_	_	_
20-45	3575-3584	increased	abstract[187]	new[187]	_	_
20-46	3585-3591	levels	abstract[187]	new[187]	_	_
20-47	3592-3594	of	abstract[187]	new[187]	_	_
20-48	3595-3600	IL-13	abstract[187]|abstract	new[187]|new	_	_
20-49	3601-3602	,	abstract[187]	new[187]	_	_
20-50	3603-3607	IL-2	abstract[187]|abstract	new[187]|new	_	_
20-51	3608-3609	,	abstract[187]	new[187]	_	_
20-52	3610-3613	and	abstract[187]	new[187]	_	_
20-53	3614-3618	IL-6	abstract[187]|abstract[190]	new[187]|giv[190]	_	_
20-54	3619-3621	in	abstract[187]|abstract[190]	new[187]|giv[190]	_	_
20-55	3622-3628	plasma	abstract[187]|abstract[190]|place	new[187]|giv[190]|new	_	_
20-56	3629-3630	.	_	_	_	_

#Text=The systemic inflammatory environment created by the arthritis induction leads to decreased metabolic activity and proliferation of CIA-derived MSC , and increased differentiation capacity determined by the expression of osteogenic ( runt-related transcription factor 2 ( RUNX2 ) and alkaline phosphatase ( ALP ) ) , and chondrogenic ( aggrecan ( ACAN ) ) markers in basal conditions .
21-1	3631-3634	The	abstract[192]	new[192]	_	_
21-2	3635-3643	systemic	abstract[192]	new[192]	_	_
21-3	3644-3656	inflammatory	abstract[192]	new[192]	_	_
21-4	3657-3668	environment	abstract[192]	new[192]	_	_
21-5	3669-3676	created	_	_	_	_
21-6	3677-3679	by	_	_	_	_
21-7	3680-3683	the	abstract[194]	giv[194]	_	_
21-8	3684-3693	arthritis	abstract|abstract[194]	giv|giv[194]	_	_
21-9	3694-3703	induction	abstract[194]	giv[194]	_	_
21-10	3704-3709	leads	_	_	_	_
21-11	3710-3712	to	_	_	_	_
21-12	3713-3722	decreased	abstract[196]	giv[196]	_	_
21-13	3723-3732	metabolic	person|abstract[196]	new|giv[196]	_	_
21-14	3733-3741	activity	abstract[196]	giv[196]	_	_
21-15	3742-3745	and	_	_	_	_
21-16	3746-3759	proliferation	event[197]	new[197]	_	_
21-17	3760-3762	of	event[197]	new[197]	_	_
21-18	3763-3774	CIA-derived	event[197]|abstract|object[199]	new[197]|new|giv[199]	_	_
21-19	3775-3778	MSC	event[197]|object[199]	new[197]|giv[199]	_	_
21-20	3779-3780	,	_	_	_	_
21-21	3781-3784	and	_	_	_	_
21-22	3785-3794	increased	_	_	_	_
21-23	3795-3810	differentiation	abstract|abstract[201]	new|new[201]	_	_
21-24	3811-3819	capacity	abstract[201]	new[201]	_	_
21-25	3820-3830	determined	_	_	_	_
21-26	3831-3833	by	_	_	_	_
21-27	3834-3837	the	abstract[202]	giv[202]	_	_
21-28	3838-3848	expression	abstract[202]	giv[202]	_	_
21-29	3849-3851	of	abstract[202]	giv[202]	_	_
21-30	3852-3862	osteogenic	abstract[202]|abstract	giv[202]|new	_	_
21-31	3863-3864	(	abstract[202]	giv[202]	_	_
21-32	3865-3877	runt-related	abstract[202]|abstract[205]	giv[202]|new[205]	appos	21-37[0_205]
21-33	3878-3891	transcription	abstract[202]|abstract|abstract[205]	giv[202]|new|new[205]	_	_
21-34	3892-3898	factor	abstract[202]|abstract[205]	giv[202]|new[205]	_	_
21-35	3899-3900	2	abstract[202]|abstract[205]	giv[202]|new[205]	_	_
21-36	3901-3902	(	abstract[202]	giv[202]	_	_
21-37	3903-3908	RUNX2	abstract[202]|abstract	giv[202]|giv	_	_
21-38	3909-3910	)	abstract[202]	giv[202]	_	_
21-39	3911-3914	and	abstract[202]	giv[202]	_	_
21-40	3915-3923	alkaline	abstract[202]|abstract[207]	giv[202]|new[207]	appos	21-43[0_207]
21-41	3924-3935	phosphatase	abstract[202]|abstract[207]	giv[202]|new[207]	_	_
21-42	3936-3937	(	_	_	_	_
21-43	3938-3941	ALP	abstract	giv	_	_
21-44	3942-3943	)	_	_	_	_
21-45	3944-3945	)	_	_	_	_
21-46	3946-3947	,	_	_	_	_
21-47	3948-3951	and	_	_	_	_
21-48	3952-3964	chondrogenic	abstract[209]	new[209]	_	_
21-49	3965-3966	(	abstract[209]	new[209]	_	_
21-50	3967-3975	aggrecan	abstract[209]|person	new[209]|new	_	_
21-51	3976-3977	(	abstract[209]	new[209]	_	_
21-52	3978-3982	ACAN	abstract[209]|abstract	new[209]|new	_	_
21-53	3983-3984	)	abstract[209]	new[209]	_	_
21-54	3985-3986	)	abstract[209]	new[209]	_	_
21-55	3987-3994	markers	abstract[209]|abstract[212]	new[209]|new[212]	_	_
21-56	3995-3997	in	abstract[209]|abstract[212]	new[209]|new[212]	_	_
21-57	3998-4003	basal	abstract[209]|abstract[212]|abstract[213]	new[209]|new[212]|giv[213]	_	_
21-58	4004-4014	conditions	abstract[209]|abstract[212]|abstract[213]	new[209]|new[212]|giv[213]	_	_
21-59	4015-4016	.	_	_	_	_
